GRI Bio GRI 深 滬
等待開盤 01-13 09:30:00 美东时间
0.242
+0.017
+7.56%
華盛通- 最 高0.242
- 今 開0.239
- 成交量 181.25万股
- 最 低 0.222
- 昨 收 0.225
- 總市值 70.85万
- 52周最高 12.58
- 市盈率 靜 --
- 換手率 61.91%
- 52周最低 0.19
- 委 比 -23.46%
- 總股本 292.77万
- 歷史最高 2314002.60
- 量 比 0.46
- 振 幅 8.89%
- 歷史最低 0.19
- 每 手 1
- 風險率 3.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GRI Bio Expands At-The-Market Equity Offering Capacity
The latest announcement is out from GRI Bio ( ($GRI) ). On January 9, 2026, GRI...
01-09 21:59
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares moved upwards by 14.1% to...
01-09 05:06
GRI Bio Announced Cytometry Data From Phase 2a GRI-0621-IPF-02 Clinical Trial Evaluating GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung functionLA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc.
01-08 21:03
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
GRI Bio, Inc. announced positive data from its Phase 2a clinical trial for GRI-0621, showing immune cell modulation in Idiopathic Pulmonary Fibrosis (IPF) patients. The study revealed inhibition of iNKT cells, increased anti-fibrotic cytokines (IFN-γ), and reduced pro-fibrotic cytokines (IL-4, IL-13, IL-17A, IL-22, TGF-β). T cell receptor expression also increased after 12 weeks of treatment. The results reinforce GRI-0621's potential as a diseas...
01-08 13:00
Why Fonar Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
Shares of Fonar Corp (NASDAQ:FONR) rose sharply in pre-market after the company...
2025-12-30 17:43
GRI Bio Launches $6.7 Million Public Offering
GRI Bio ( ($GRI) ) has shared an update. On December 11, 2025, GRI Bio, Inc. in...
2025-12-12 22:00
GRI Bio Announces Pricing of $8,000,000 Million Public Offering
<p>GRI Bio, Inc. announced a public stock offering of approximately 10.7 million shares and accompanying Series F warrants, priced at $0.75 per share. Proceeds from the offering are expected to be $8 million, with potential additional $8 million from warrant exercises. The company plans to use the funds for product development and general corporate purposes. GRI Bio is a biotech company developing therapies targeting NKT cells for inflammatory an...
2025-12-11 14:15
AI Data Center Rush Triggers Eaton's $50 Million-Plus Expansion In Virginia
Eaton Corp. (NYSE: ETN) stock rose on $50M investment in new Virginia facility to meet surging demand for data centers.
2025-12-11 01:30
美股机会日报 | 特朗普最新讲话：可能降低部分商品关税！美联储传声筒称鲍威尔或“先降息再设限”
特朗普最新讲话：可能降低部分商品关税；美联储传声筒称鲍威尔或“先降息再设限”；阿里巴巴成立千问C端事业群，但盘前仍跌约2%>>
2025-12-09 21:20
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
2025-12-09 10:32
